Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin

Morten Frost, Tom E. Andersen, Vijay Yadav, Kim Brixen, Gerard Karsenty, Moustapha Kassem

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 2010-Jan-29
OriginalsprogEngelsk
TidsskriftJournal of Bone and Mineral Research
Vol/bind25
Udgave nummer3
Sider (fra-til)673-675
Antal sider2
ISSN0884-0431
DOI
StatusUdgivet - 29. jan. 2010

Fingeraftryk

Mutation
Osteogenesis

Citer dette

@article{e7ac6b403a7711df937d000ea68e967b,
title = "Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin",
abstract = "The Lrp5 gene is a major determinant of bone mass accrual. It has been demonstrated recently to achieve this function by hampering the synthesis of gut-derived serotonin, which is a powerful inhibitor of bone formation. In this study we analyzed plasma serotonin levels in patients with a high-bone-mass (HBM) phenotype owing to gain-of-function mutation of Lrp5 (T253I). A total of 9 HBM patients were compared with 18 sex- and age-matched controls. In HBM patients, the serotonin concentrations in platelet-poor plasma were significantly lower than in the controls (mean +/- SEM: 2.16 +/- 0.28 ng/mL versus 3.51 +/- 0.49 ng/mL, respectively, p < .05). Our data support the hypothesis that circulating serotonin levels mediate the increased bone mass resulting from gain-of-function mutations in Lrp5 in humans. (c) 2010 American Society for Bone and Mineral Research.",
author = "Morten Frost and Andersen, {Tom E.} and Vijay Yadav and Kim Brixen and Gerard Karsenty and Moustapha Kassem",
year = "2010",
month = "1",
day = "29",
doi = "10.1002/jbmr.44",
language = "English",
volume = "25",
pages = "673--675",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "3",

}

Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. / Frost, Morten; Andersen, Tom E.; Yadav, Vijay; Brixen, Kim; Karsenty, Gerard; Kassem, Moustapha.

I: Journal of Bone and Mineral Research, Bind 25, Nr. 3, 29.01.2010, s. 673-675.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin

AU - Frost, Morten

AU - Andersen, Tom E.

AU - Yadav, Vijay

AU - Brixen, Kim

AU - Karsenty, Gerard

AU - Kassem, Moustapha

PY - 2010/1/29

Y1 - 2010/1/29

N2 - The Lrp5 gene is a major determinant of bone mass accrual. It has been demonstrated recently to achieve this function by hampering the synthesis of gut-derived serotonin, which is a powerful inhibitor of bone formation. In this study we analyzed plasma serotonin levels in patients with a high-bone-mass (HBM) phenotype owing to gain-of-function mutation of Lrp5 (T253I). A total of 9 HBM patients were compared with 18 sex- and age-matched controls. In HBM patients, the serotonin concentrations in platelet-poor plasma were significantly lower than in the controls (mean +/- SEM: 2.16 +/- 0.28 ng/mL versus 3.51 +/- 0.49 ng/mL, respectively, p < .05). Our data support the hypothesis that circulating serotonin levels mediate the increased bone mass resulting from gain-of-function mutations in Lrp5 in humans. (c) 2010 American Society for Bone and Mineral Research.

AB - The Lrp5 gene is a major determinant of bone mass accrual. It has been demonstrated recently to achieve this function by hampering the synthesis of gut-derived serotonin, which is a powerful inhibitor of bone formation. In this study we analyzed plasma serotonin levels in patients with a high-bone-mass (HBM) phenotype owing to gain-of-function mutation of Lrp5 (T253I). A total of 9 HBM patients were compared with 18 sex- and age-matched controls. In HBM patients, the serotonin concentrations in platelet-poor plasma were significantly lower than in the controls (mean +/- SEM: 2.16 +/- 0.28 ng/mL versus 3.51 +/- 0.49 ng/mL, respectively, p < .05). Our data support the hypothesis that circulating serotonin levels mediate the increased bone mass resulting from gain-of-function mutations in Lrp5 in humans. (c) 2010 American Society for Bone and Mineral Research.

U2 - 10.1002/jbmr.44

DO - 10.1002/jbmr.44

M3 - Journal article

C2 - 20200960

VL - 25

SP - 673

EP - 675

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 3

ER -